These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 6801826)

  • 1. Role of the crossmatch in testing for serologic incompatibility.
    Oberman HA; Barnes BA; Steiner EA
    Transfusion; 1982; 22(1):12-6. PubMed ID: 6801826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransfusion blood group serology. Limited value of the antiglobulin phase of the crossmatch when a careful screening test for unexpected antibodies is performed.
    Heistø H
    Transfusion; 1979; 19(6):761-3. PubMed ID: 118557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of the immediate spin crossmatch when used for detecting ABO incompatibility.
    Berry-Dortch S; Woodside CH; Boral LI
    Transfusion; 1985; 25(2):176-8. PubMed ID: 3984013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three low-ionic-strength solutions for routine pretransfusion testing: antibody screening/identification, cross-matching, immune anti-ABO detection, and direct antiglobulin tests.
    Kaspi E; Mallié F; Gouvitsos J; Dettori I; Chiaroni J; Ferrera V
    Transfusion; 2009 Dec; 49(12):2772-3. PubMed ID: 20163691
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing.
    Heddle NM; O'Hoski P; Singer J; McBride JA; Ali MA; Kelton JG
    Br J Haematol; 1992 Aug; 81(4):579-84. PubMed ID: 1390245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do you think that the cross match with donor red cells can be omitted when the serum of a patient has been tested for the presence of red cell alloantibodies with a cell panel?
    Vox Sang; 1982; 43(3):151-68. PubMed ID: 6815895
    [No Abstract]   [Full Text] [Related]  

  • 7. [The importance of immunohematology testing in the neonatal period].
    Bujandrić N; Milanović MK
    Med Pregl; 2013; 66(7-8):317-21. PubMed ID: 24069814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incompatible crossmatch following nonreactive antibody detection test. Frequency and cause.
    Mintz PD; Haines AL; Sullivan MF
    Transfusion; 1982; 22(2):107-10. PubMed ID: 7071913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Test for blood group incompatibility in pregnancy].
    Okubo M; Tate A; Maeda H; Suzuki M
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():803-6. PubMed ID: 20942195
    [No Abstract]   [Full Text] [Related]  

  • 10. Electronic verification of donor-recipient compatibility: the computer crossmatch.
    Butch SH; Judd WJ; Steiner EA; Stoe M; Oberman HA
    Transfusion; 1994 Feb; 34(2):105-9. PubMed ID: 8310478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Irregular agglutinins and the compatibility test: the elements of choice].
    Rouger P; Salmon C
    Rev Fr Transfus Immunohematol; 1983 Feb; 26(1):5-13. PubMed ID: 6407087
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathology consultation on electronic crossmatch.
    Mazepa MA; Raval JS; Park YA;
    Am J Clin Pathol; 2014 May; 141(5):618-24. PubMed ID: 24713731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a manual hexadimethrine bromide-antiglobulin test with saline- and albumin-antiglobulin tests for pretransfusion testing.
    Mintz PD; Anderson G
    Transfusion; 1987; 27(2):134-7. PubMed ID: 3824470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythrocyte detection with the immunoperoxidase method following 2 failed transfusions in ABO and Rhesus incompatibility--clinical course].
    Heim MU; Pachmann U; Böck M; Geschwändler E; Schleifer A; Eckstein R; Mempel W
    Beitr Infusionsther; 1988; 21():255-8. PubMed ID: 2462987
    [No Abstract]   [Full Text] [Related]  

  • 15. [Analysis of the causes of incompatible cross-matching induced by two Rh blood group antibodies and corresponding laboratory treatment].
    Cui Y; Zhang Y; Yang S; Xu Y; Qi X; Xing Y; An N; Wang B
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jul; 40(7):623-628. PubMed ID: 39179405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of compatibility tests. (Report of a meeting sponsored by the Bureau of Biologics for the Blood Products Advisory Committee).
    Garratty G
    Transfusion; 1982; 22(2):169-72. PubMed ID: 6803410
    [No Abstract]   [Full Text] [Related]  

  • 17. Pretransfusion testing without serologic crossmatch: approaches to ensure patient safety.
    Kuriyan M; Fox E
    Vox Sang; 2000; 78(2):113-8. PubMed ID: 10765147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with the routine use of an abbreviated crossmatch.
    Shulman IA; Nelson JM; Saxena S; Thompson JC; Okamoto M; Kent DR; Nakayama RK
    Am J Clin Pathol; 1984 Aug; 82(2):178-81. PubMed ID: 6465079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety in transfusion practice. Is it safe to eliminate the major crossmatch for selected patients?
    Shulman IA; Kent D
    Arch Pathol Lab Med; 1989 Mar; 113(3):270-2. PubMed ID: 2919957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The gel centrifugation test in serologic compatibility testing].
    Hitzler W; Bauernfeind U; Schömig-Brekner J; Mathias D
    Beitr Infusionsther; 1990; 26():358-61. PubMed ID: 1703871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.